Literature DB >> 23532615

Macular choroidal blood flow velocity decreases with regression of acute central serous chorioretinopathy.

Michiyuki Saito1, Wataru Saito, Yuki Hashimoto, Chikako Yoshizawa, Akio Fujiya, Kousuke Noda, Susumu Ishida.   

Abstract

AIM: To quantitatively evaluate the time course of macular choroidal blood flow velocity in acute central serous chorioretinopathy (CSC).
METHODS: This retrospective observational case series included 21 eyes of 20 patients (17 men, 3 women; mean age, 53.0 years) with treatment-naïve acute CSC. Laser speckle flowgraphy was performed to calculate macular mean blur rate (MBR), an indicator of relative blood flow velocity at the first visit, 3 and 6 months thereafter. Changes in average MBR values were compared with visual improvement at 6 months.
RESULTS: Subretinal fluid completely resolved in all eyes within 6 months, while best-corrected visual acuity (BCVA) significantly improved at 6 months compared to the initial BCVA. During the follow-up period, the average MBR significantly decreased to 92.8% and 82.3% at 3 and 6 months, respectively, against baseline (100%). Importantly, there was a negative correlation between the BCVA recovery and the MBR decrease, showing the possible association of MBR increase with poor visual prognosis. Multiple regression analysis demonstrated no significant correlation between MBR and ocular perfusion pressure.
CONCLUSIONS: These results indicate that macular choroidal blood flow velocity decreases concurrently with regression of CSC, suggesting a validity of choroidal blood flow elevation in the pathogenesis of acute CSC.

Entities:  

Mesh:

Year:  2013        PMID: 23532615     DOI: 10.1136/bjophthalmol-2012-302349

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  33 in total

1.  Increased choroidal blood flow velocity with regression of unilateral acute idiopathic maculopathy.

Authors:  Yuki Hashimoto; Wataru Saito; Michiyuki Saito; Kiriko Hirooka; Shohei Mori; Kousuke Noda; Susumu Ishida
Journal:  Jpn J Ophthalmol       Date:  2015-04-23       Impact factor: 2.447

2.  Decreased choroidal blood flow velocity in the pathogenesis of multiple evanescent white dot syndrome.

Authors:  Yuki Hashimoto; Wataru Saito; Michiyuki Saito; Kiriko Hirooka; Shohei Mori; Kousuke Noda; Susumu Ishida
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-10-24       Impact factor: 3.117

3.  Assessment of ocular microcirculation in patients with end-stage kidney disease.

Authors:  Tetsushi Arimura; Tomoaki Shiba; Mao Takahashi; Shun Kumashiro; Hironori Osamura; Tadashi Matsumoto; Ken Sakai; Yuichi Hori
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2018-09-10       Impact factor: 3.117

4.  Increased choroidal blood flow velocity with regression of acute posterior multifocal placoid pigment epitheliopathy.

Authors:  Kiriko Hirooka; Wataru Saito; Michiyuki Saito; Yuki Hashimoto; Shohei Mori; Kousuke Noda; Susumu Ishida
Journal:  Jpn J Ophthalmol       Date:  2016-03-28       Impact factor: 2.447

5.  Relationship between choroidal blood flow velocity and choroidal thickness in patients with regression of acute central serous chorioretinopathy.

Authors:  Michiyuki Saito; Kousuke Noda; Wataru Saito; Susumu Ishida
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2017-09-09       Impact factor: 3.117

6.  Effects of intravitreal injection of ranibizumab on choroidal structure and blood flow in eyes with diabetic macular edema.

Authors:  Masahiro Okamoto; Mariko Yamashita; Nahoko Ogata
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2018-03-01       Impact factor: 3.117

7.  Increased choroidal blood flow and choroidal thickness in patients with hypertensive chorioretinopathy.

Authors:  Michiyuki Saito; Kousuke Noda; Wataru Saito; Kiriko Hirooka; Yuki Hashimoto; Susumu Ishida
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2019-11-14       Impact factor: 3.117

8.  Relationship between choroidal blood flow velocity and choroidal thickness during systemic corticosteroid therapy for Vogt-Koyanagi-Harada disease.

Authors:  Kiriko Hirooka; Wataru Saito; Kenichi Namba; Yuko Takemoto; Kazuomi Mizuuchi; Tomoe Uno; Yoshiaki Tagawa; Yuki Hashimoto; Susumu Ishida
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2015-01-27       Impact factor: 3.117

9.  Mitochondrial DNA as a Biomarker for Acute Central Serous Chorioretinopathy: A Case-Control Study.

Authors:  Noriyasu Hashida; Kazunobu Asao; Chikako Hara; Andrew J Quantock; Ryotaro Saita; Hiroyuki Kurakami; Kazuichi Maruyama; Kohji Nishida
Journal:  Front Med (Lausanne)       Date:  2022-06-21

10.  Decrease in choroidal blood flow after half and one-third dose verteporfin photodynamic therapy for chronic central serous chorioretinopathy.

Authors:  Shun Kumashiro; Seiji Takagi; Takashi Itokawa; Akiko Tajima; Tatsuhiko Kobayashi; Yuichi Hori
Journal:  BMC Ophthalmol       Date:  2021-05-31       Impact factor: 2.209

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.